サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1739285

結核診断の世界市場

Tuberculosis Diagnostics

出版日
ページ情報
英文 284 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
結核診断の世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 284 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

結核診断の世界市場は2030年までに26億米ドルに到達

2024年に22億米ドルと推定される結核診断の世界市場は、2024年から2030年にかけてCAGR 2.8%で成長し、2030年には26億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである培養に基づく診断は、CAGR 1.9％を記録し、分析期間終了までに11億米ドルに達すると予測されます。喀痰検査セグメントの成長率は、分析期間中CAGR 3.7%と推定されます。

米国市場は6億140万米ドルと推定、中国はCAGR 5.1％で成長予測

米国の結核診断市場は、2024年に6億140万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.1%として、2030年までに5億30万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.0%と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界の結核診断市場- 主要動向と促進要因まとめ

なぜ結核は21世紀になっても診断の課題なのか？

結核は予防可能かつ治癒可能な病気であるにもかかわらず、特に中低所得国において、公衆衛生上の大きな課題となっています。結核との世界の闘いにおける最大の難関のひとつは、特に小児、HIV感染者、遠隔地や資源不足の地域の人々といった脆弱な人々の間で、結核をタイムリーかつ正確に診断することです。喀痰塗抹顕微鏡検査のような伝統的な方法は、広く用いられているもの、特に肺外結核や潜在性結核の場合、感度が低いという問題を抱えています。さらに、培養法には長い納期がかかり、多くの流行地域ではインフラや熟練した人材が限られているため、高度な診断ソリューションを大規模に実施することは困難です。結核の多様な臨床症状や他の呼吸器疾患との類似性は、診断をさらに複雑にし、しばしば誤診や治療の遅れにつながります。このような制約から、感染と治療のギャップを埋めるため、より迅速で正確、かつ利用しやすい診断技術が緊急に必要であることが浮き彫りになっています。

新しい技術は結核の診断状況をどのように破壊しているのか？

近年、結核の検出をより迅速、正確、かつ利用しやすくすることを目的とした診断技術の革新が爆発的に進んでいます。分子診断ツール、特にGeneXpertやTruenatのような核酸増幅検査（NAAT）は、結核や多剤耐性結核（MDR-TB）を数時間以内に検出する能力を大幅に向上させました。これらのポイント・オブ・ケア技術は、複雑な検査インフラを必要とせずに迅速な診断を可能にするため、現場の診療所や農村部の保健センターで導入されています。NAATに加え、インターフェロン-γ放出測定法（IGRA）や結核LAM抗原検査などの画期的な技術により、特にHIV感染者や小児環境における診断の選択肢が広がっています。人工知能も胸部X線判読の向上に応用され、デジタル診断プラットフォームは検体追跡、データ記録、疫学マッピングを改善しています。診断とモバイル・ヘルス・ソリューションの融合により、遠隔での診察、フォローアップ、意思決定の一元化が可能になり、結核の罹患率が高く、医療システムが分断されている国々では特に有用です。

世界のユニバーサル・ヘルス・カバレッジの推進は結核診断へのアクセスに影響を与えているか？

ユニバーサル・ヘルス・カバレッジ（UHC）に向けた世界の動きと国連の結核撲滅戦略は、撲滅に向けた基本的なステップとして、診断アクセスの改善を各国政府や国際機関に圧力をかけています。WHO、世界基金、UNITAIDのような多国間機関は、手頃な価格と拡張性に焦点を当て、診断ツールの開発、調達、配布に積極的に資金を提供しています。各国の結核プログラムでは、早期発見をより現実的かつ分散的にするため、迅速分子診断法をプライマリー・ヘルスケア・センターに統合するよう促されています。これと並行して、手頃な価格の診断キットを開発し、サプライチェーンのボトルネックを克服するための現地製造能力を開発するための官民パートナーシップが生まれつつあります。しかし、都市と農村の格差や手ごろな価格の問題から、診断の公平性が依然として課題となっています。一部の政府は、結核検査とHIV、COVID-19、肝炎のスクリーニングを組み合わせた総合的な疾患検査プラットフォームを採用しており、これは検出率を高めるだけでなく、医療システムの効率も向上させる。このような複数疾患検査の枠組みは、高リスク集団における結核診断の普及を促進すると期待されています。

結核診断市場の成長の原動力は？

結核診断市場の成長は、人口密度の高いハイリスク地域における世界の結核罹患率の上昇、感染症管理に対する公衆衛生投資の増加、分子診断ツールの急速な普及など、いくつかの要因によってもたらされます。地域診療所や移動診療ユニットにおけるポイント・オブ・ケア検査への嗜好の高まりなど、最終用途の行動がポータブル迅速診断薬の需要を押し上げています。さらに、薬剤耐性結核菌株の出現により、結核病原体とともに耐性マーカーを検出できる高度な分子プラットフォームの採用が増加しています。世界保健機関や各国政府からの資金援助も、特にアフリカ、東南アジア、東欧の流行国における診断ツールの展開を加速させています。マルチプレックス検査、サンプルプール、結果の自動解釈といった技術動向は、運用の拡張性をさらに高めています。消費者の行動も変化しており、COVID以降、結核の症状や検査手段に対する認識が高まり、早期診断を求める積極性が高まっています。

セグメント

タイプ（培養ベース診断、喀痰検査、迅速分子診断、その他のタイプ）、エンドユーザー（病院、診断ラボ、その他のエンドユーザー）

調査対象企業の例（注目の44社）

  • Abbott Laboratories
  • AdvaCare Pharma
  • Becton, Dickinson and Company（BD）
  • bioMerieux SA
  • Cepheid（Danaher Corporation）
  • DiaSorin S.p.A.
  • FIND（Foundation for Innovative New Diagnostics）
  • F. Hoffmann-La Roche AG
  • Hain Lifescience GmbH
  • Hologic, Inc.
  • JN-International Medical Corporation
  • Lionex GmbH
  • Lupin Limited
  • Novosibirsk TB Research Institute
  • Oxford Immunotec Ltd.
  • QIAGEN N.V.
  • R-Biopharm AG
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34450

Global Tuberculosis Diagnostics Market to Reach US$2.6 Billion by 2030

The global market for Tuberculosis Diagnostics estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. Culture based Diagnosis, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Sputum Test segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$601.4 Million While China is Forecast to Grow at 5.1% CAGR

The Tuberculosis Diagnostics market in the U.S. is estimated at US$601.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$500.3 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Tuberculosis Diagnostics Market - Key Trends & Drivers Summarized

Why Is Tuberculosis Still a Diagnostic Challenge in the 21st Century?

Despite being a preventable and curable disease, tuberculosis (TB) continues to pose a major public health challenge, especially in low- and middle-income countries. One of the biggest hurdles in the global fight against TB is the timely and accurate diagnosis of the disease, particularly among vulnerable populations such as children, people living with HIV, and individuals in remote or under-resourced areas. Traditional methods like sputum smear microscopy, though widely used, suffer from low sensitivity, especially in cases of extrapulmonary and latent TB. Moreover, the long turnaround time associated with culture methods and the limitations in infrastructure and skilled personnel in many endemic regions make advanced diagnostic solutions difficult to implement at scale. TB's variable clinical manifestations and similarities with other respiratory illnesses further complicate diagnosis, often leading to misdiagnosis or delayed treatment. These limitations underscore the urgent need for faster, more accurate, and accessible diagnostic technologies to help bridge the gap between infection and intervention.

How Are New Technologies Disrupting the Diagnostic Landscape for TB?

Recent years have seen an explosion in diagnostic innovations aimed at making TB detection faster, more accurate, and accessible. Molecular diagnostic tools, particularly nucleic acid amplification tests (NAATs) like GeneXpert and Truenat, have significantly improved the ability to detect TB and multidrug-resistant TB (MDR-TB) within hours. These point-of-care technologies are being deployed in field clinics and rural health centers, where they allow for rapid diagnosis without the need for complex lab infrastructure. In addition to NAATs, other breakthroughs such as interferon-gamma release assays (IGRAs) and TB LAM antigen tests are expanding diagnostic options, especially for people with HIV or in pediatric settings. Artificial intelligence is also being applied to enhance chest X-ray interpretation, while digital diagnostic platforms are improving sample tracking, data recording, and epidemiological mapping. The convergence of diagnostics with mobile health solutions enables remote consultations, follow-ups, and centralized decision-making, particularly valuable in countries with high TB burdens and fragmented healthcare systems.

Is the Global Push for Universal Health Coverage Influencing TB Diagnostic Access?

The global movement toward Universal Health Coverage (UHC) and the United Nations' End TB Strategy are exerting pressure on governments and international agencies to improve diagnostic access as a fundamental step toward eradication. Multilateral organizations like the WHO, Global Fund, and UNITAID are actively funding diagnostic tool development, procurement, and distribution, with a focus on affordability and scalability. National TB programs are being urged to integrate rapid molecular diagnostics into primary healthcare centers, making early detection more feasible and decentralized. In parallel, public-private partnerships are emerging to develop affordable diagnostic kits and local manufacturing capacities to overcome supply chain bottlenecks. However, diagnostic equity remains a challenge, with urban-rural disparities and affordability issues limiting reach. Some governments are adopting integrated disease testing platforms that combine TB testing with HIV, COVID-19, and hepatitis screening, which not only enhances detection but also improves healthcare system efficiency. These multi-disease testing frameworks are expected to drive increased uptake of TB diagnostics across high-risk populations.

What Is Driving Growth in the Tuberculosis Diagnostics Market?

The growth in the tuberculosis diagnostics market is driven by several factors, including the rising global TB incidence in densely populated and high-risk regions, increasing public health investments in infectious disease management, and rapid adoption of molecular diagnostic tools. End-use behavior, such as a growing preference for point-of-care testing in community clinics and mobile health units, is pushing the demand for portable, rapid diagnostics. Additionally, the emergence of drug-resistant TB strains has led to increased adoption of advanced molecular platforms capable of detecting resistance markers alongside TB pathogens. Funding from global health bodies and national governments is also accelerating the deployment of diagnostic tools, especially in endemic countries in Africa, Southeast Asia, and Eastern Europe. Technological trends such as multiplex testing, sample pooling, and automated result interpretation are further enhancing operational scalability. Consumer behavior is also shifting, with heightened awareness about TB symptoms and testing avenues post-COVID, making individuals more proactive in seeking early diagnosis - a factor that will continue to fuel diagnostic volumes globally.

SCOPE OF STUDY:

The report analyzes the Tuberculosis Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis, Other Types); End-Use (Hospitals, Diagnostic Labs, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • AdvaCare Pharma
  • Becton, Dickinson and Company (BD)
  • bioMerieux SA
  • Cepheid (Danaher Corporation)
  • DiaSorin S.p.A.
  • FIND (Foundation for Innovative New Diagnostics)
  • F. Hoffmann-La Roche AG
  • Hain Lifescience GmbH
  • Hologic, Inc.
  • JN-International Medical Corporation
  • Lionex GmbH
  • Lupin Limited
  • Novosibirsk TB Research Institute
  • Oxford Immunotec Ltd.
  • QIAGEN N.V.
  • R-Biopharm AG
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Tuberculosis Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Adoption of Rapid Molecular Testing Platforms Drives Early Detection and Case Management
    • Increasing Focus on Drug-Resistant TB Surveillance Strengthens Market Need for Genotypic Tools
    • Integration of AI in X-Ray Screening Expands Diagnostic Reach in Resource-Limited Settings
    • Public Health Funding and Global Donor Programs Propel Growth of Point-of-Care Diagnostics
    • Shift Toward Decentralized Testing Models Drives Demand for Portable and Compact Devices
    • Rising Co-Infection with HIV Accelerates Demand for Dual and Multiplex Testing Kits
    • Government Mandates for TB Case Notification Systems Spur Diagnostic Infrastructure Investments
    • Regulatory Approvals for Novel Antigen-Based Tests Expand Testing in Pediatric Populations
    • Expansion of Mobile and Remote Diagnostic Units Sustains Outreach in Rural Areas
    • Inclusion of TB Testing in Universal Health Coverage Expands Access and Market Size
    • Digital Reporting and Sample Tracking Platforms Drive Operational Efficiency in Testing Labs
    • Demand for Cost-Effective, High-Sensitivity Tools Creates Market Entry Opportunities for Local Players
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tuberculosis Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tuberculosis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Culture based Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Culture based Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Culture based Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Sputum Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Sputum Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Sputum Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rapid Molecular Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rapid Molecular Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Rapid Molecular Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Tuberculosis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Tuberculosis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Tuberculosis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Tuberculosis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION